Foghorn Therapeutics Inc.
FHTX5.125USD
+0.135+2.71%
交易中 （美東）報價延遲15分鐘
285.57M總市值
虧損本益比TTM
關於 Foghorn Therapeutics Inc. 公司
Foghorn Therapeutics Inc. 是一家臨牀階段的生物技術公司，致力於開發通過選擇性靶向染色質調節系統來調節基因表達的藥物，用於腫瘤治療干預。其基因流量控制平臺提供了對染色質調節系統各個組成部分如何相互作用的綜合、機制理解，從而可以識別、驗證系統內的潛在藥物靶點。該公司的流量控制平臺發現和開發腫瘤學和其他治療領域的藥物，包括病毒學、自身免疫性疾病和神經病學。該公司正在開發 FHD-286，一種選擇性變構 ATPase 抑制劑，正在評估轉移性葡萄膜黑素瘤和復發和/或難治性急性髓細胞白血病以及骨髓增生異常綜合徵的兩項獨立 I 期研究。該公司還在開發 FHD-909，這是一種高效、變構且可口服的小分子。
公司簡介
公司代碼FHTX
公司名稱Foghorn Therapeutics Inc.
上市日期Oct 23, 2020
CEOMr. Adrian Gottschalk
員工數量112
證券類型Ordinary Share
年結日Oct 23
公司地址500 Technology Square
城市CAMBRIDGE
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02139
電話16175863100
網址https://foghorntx.com/
公司代碼FHTX
上市日期Oct 23, 2020
CEOMr. Adrian Gottschalk
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Adrian Gottschalk
Mr. Adrian Gottschalk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
511.70K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Independent Director
Independent Director
72.07K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
B. Lynne Parshall ,J.D.
B. Lynne Parshall ,J.D.
Independent Director
Independent Director
--
--
Mr. Kristian F. Humer
Mr. Kristian F. Humer
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Thomas J. (Tom) Lynch, Jr., M.D.
Dr. Thomas J. (Tom) Lynch, Jr., M.D.
Independent Director
Independent Director
--
--
Dr. Adm. Balkrishan (Simba) Gill, Ph.D.
Dr. Adm. Balkrishan (Simba) Gill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas G. (Doug) Cole, M.D.
Dr. Douglas G. (Doug) Cole, M.D.
Independent Director
Independent Director
--
--
Dr. Alfonso Quints-Cardama, M.D.
Dr. Alfonso Quints-Cardama, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anna Rivkin, Ph.D.
Dr. Anna Rivkin, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Adrian Gottschalk
Mr. Adrian Gottschalk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
511.70K
--
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Independent Director
Independent Director
72.07K
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
B. Lynne Parshall ,J.D.
B. Lynne Parshall ,J.D.
Independent Director
Independent Director
--
--
Mr. Kristian F. Humer
Mr. Kristian F. Humer
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Thomas J. (Tom) Lynch, Jr., M.D.
Dr. Thomas J. (Tom) Lynch, Jr., M.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Flagship Ventures
22.74%
Fidelity Management & Research Company LLC
10.02%
BVF Partners L.P.
9.51%
Eli Lilly and Company
7.18%
Kadoch (Cigall)
6.55%
Other
44.00%
持股股東
持股股東
佔比
Flagship Ventures
22.74%
Fidelity Management & Research Company LLC
10.02%
BVF Partners L.P.
9.51%
Eli Lilly and Company
7.18%
Kadoch (Cigall)
6.55%
Other
44.00%
股東類型
持股股東
佔比
Venture Capital
23.64%
Investment Advisor
22.33%
Hedge Fund
17.63%
Corporation
11.01%
Individual Investor
8.07%
Investment Advisor/Hedge Fund
4.34%
Research Firm
4.25%
Pension Fund
0.16%
Bank and Trust
0.07%
Other
8.51%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
175
51.00M
91.49%
-1.63M
2025Q1
185
53.19M
95.48%
+394.99K
2024Q4
178
53.30M
95.87%
+921.79K
2024Q3
184
50.70M
91.53%
+23.79K
2024Q2
177
50.15M
91.83%
+3.64M
2024Q1
178
37.16M
87.23%
-1.25M
2023Q4
175
36.77M
87.30%
-2.14M
2023Q3
182
37.73M
90.13%
-1.82M
2023Q2
179
37.64M
89.97%
-896.62K
2023Q1
182
37.04M
88.82%
-2.48M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Flagship Ventures
12.67M
22.74%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.59M
10.02%
-102.00K
-1.79%
Mar 31, 2025
BVF Partners L.P.
5.30M
9.51%
--
--
Mar 31, 2025
Eli Lilly and Company
4.00M
7.18%
--
--
Apr 23, 2025
Kadoch (Cigall)
3.65M
6.55%
+28.53K
+0.79%
Apr 23, 2025
Deerfield Management Company, L.P.
3.26M
5.84%
--
--
Mar 31, 2025
Raymond James & Associates, Inc.
2.22M
3.98%
+188.97K
+9.31%
Mar 31, 2025
The Klarman Family Foundation
2.14M
3.84%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
1.83M
3.29%
+84.97K
+4.86%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.83M
3.29%
-30.08K
-1.62%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
查看更多
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
iShares Micro-Cap ETF
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
Global X Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
